Tiziana life sciences announces invitation for podium presentation of research on intranasal anti-cd3 mab in intracerebral hemorrhage at the annual american academy of neurology conference

New york, april 04, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that dr. saef izzy will present pre-clinical data on the effects of intranasal anti-cd3 monoclonal antibody in an animal model of intracerebral hemorrhage (hemorrhagic stroke) on april 23, 2023, at 2:48 pm at neurocritical care scientific platform session at the prestigious annual american academy of neurology (aan) conference in boston, ma.
TLSA Ratings Summary
TLSA Quant Ranking